<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/505701EA-1757-4736-A8D4-2674E3A349C2"><gtr:id>505701EA-1757-4736-A8D4-2674E3A349C2</gtr:id><gtr:name>University of Oulu</gtr:name><gtr:address><gtr:line1>P.O. Box 4200</gtr:line1><gtr:line4>Oulu</gtr:line4><gtr:line5>FI-90014</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E84BEA72-2F6E-4D2A-A1CE-1A854B2298E6"><gtr:id>E84BEA72-2F6E-4D2A-A1CE-1A854B2298E6</gtr:id><gtr:name>Fuwai Cardiovascular Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D0BC4C5-96AF-4F9D-93AF-B475CFBC6944"><gtr:id>5D0BC4C5-96AF-4F9D-93AF-B475CFBC6944</gtr:id><gtr:name>Nightingale Health Ltd.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/505701EA-1757-4736-A8D4-2674E3A349C2"><gtr:id>505701EA-1757-4736-A8D4-2674E3A349C2</gtr:id><gtr:name>University of Oulu</gtr:name><gtr:address><gtr:line1>P.O. Box 4200</gtr:line1><gtr:line4>Oulu</gtr:line4><gtr:line5>FI-90014</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E84BEA72-2F6E-4D2A-A1CE-1A854B2298E6"><gtr:id>E84BEA72-2F6E-4D2A-A1CE-1A854B2298E6</gtr:id><gtr:name>Fuwai Cardiovascular Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D0BC4C5-96AF-4F9D-93AF-B475CFBC6944"><gtr:id>5D0BC4C5-96AF-4F9D-93AF-B475CFBC6944</gtr:id><gtr:name>Nightingale Health Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/35A00A06-75A4-4F97-A78C-60FCE9564F3F"><gtr:id>35A00A06-75A4-4F97-A78C-60FCE9564F3F</gtr:id><gtr:firstName>Kathy</gtr:firstName><gtr:surname>Emmens</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C245FDB4-7964-48C0-AADD-A63A7A87743A"><gtr:id>C245FDB4-7964-48C0-AADD-A63A7A87743A</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9CD2B2B5-0E81-487F-B3C3-8AB84DC0D3D3"><gtr:id>9CD2B2B5-0E81-487F-B3C3-8AB84DC0D3D3</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/47B9B737-CB14-480F-868C-9CFC32892F0A"><gtr:id>47B9B737-CB14-480F-868C-9CFC32892F0A</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Wintour</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9F1781DC-4224-4529-90DD-061E65549BBC"><gtr:id>9F1781DC-4224-4529-90DD-061E65549BBC</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Radley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137686855"><gtr:id>03753A60-2BAA-4DB9-AE29-CE1D0120AE12</gtr:id><gtr:title>Epidemiological Laboratories: Supporting Large-Scale Research</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137686855</gtr:grantReference><gtr:abstractText>CTSU?s dedicated laboratories provide critical and cost-effective support for large-scale randomised trials and observational studies, whether these are led by CTSU or other collaborating groups. In addition to CTSU projects, we are the central laboratory for clinical trials and projects run by groups based in Oxford, London and Australia and are able to support a wide range of laboratory tests, including clinical laboratory testing and specialist assays. We work closely with other academic groups; in the development of new tests and procedures, and also in helping other groups in the UK and internationally establish and run their own testing and storage facilities.
Large scale studies often involve the collection of tens of thousands of human samples from around the world and our work ensures the quality and long-term integrity of these samples. Critically, our work is focussed on ensuring the reliability of test results in large scale studies which may extend over several years. This is vital when testing new emerging risk factors in health and disease and ensuring clinical trials have accurate laboratory data.</gtr:abstractText><gtr:technicalSummary>The objectives of this programme are to provide critical and cost-effective support for large-scale observational studies and randomised trials conducted by CTSU and collaborating research groups. The CTSU Wolfson laboratories are in a strong position to support this work being accredited to the international standard ISO17025:2005 ?General requirements for the competence of testing and calibration laboratories? as a testing laboratory for many of their routine analyses. 
Large-scale research conducted by the CTSU and collaborating groups often involves the collection of tens of thousands of human samples from around the World. The biomarker/genetic assay requirements may differ between projects and this can create a unique set of challenges to provide suitable low cost methods for sample collection, processing, transport, analysis and storage. There is an ongoing need to support these areas, particularly with new opportunities and challenges with evolving technologies and ever increasing demands for new and more complex biomarker analysis.
The major elements of the programme are to investigate, and provide guidance for, various methodological aspects, such as: sample collection (e.g. blood, urine) and transport procedures; stability of biomarkers; cataloguing and storage strategies for large-scale collections; and the development of analytical methods suitable for high-throughput testing in large epidemiological study populations (without compromising the reliability or quality of the data produced). Over the next 5 years, major strategic initiatives will include investment in a high-throughput nuclear magnetic resonance (NMR) metabolomics platform at CTSU, that will use very small sample volumes, and providing laboratory training and support programmes for collaborators in the UK and internationally.
Supporting collaborating groups in the UK and internationally is an important goal in supporting knowledge transfer. For example, the CTSU laboratories provided significant support and scientific oversight of procedures adopted by UK Biobank for the sample collection, sample handling and storage of their 0.5 million biobank population. We are currently supporting them to establish testing laboratories at the UK Biobank facilities in Stockport; provide scientific oversight for their assay requirements and QA and QC procedures. In addition, we have supported Fuwai Hospital in establishing a national biocentre in Beijing, introducing a quality management system that has led to ISO accreditation. We continue to support them in the next stage as they establish their own testing laboratories which will support large scale projects in China.</gtr:technicalSummary><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>9281975</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oulu</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>NMR metabolomics for large-scale research</gtr:description><gtr:id>E849589B-1202-48E5-8873-89D2FFF65146</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dec9fe26f2a7.58165113-1</gtr:outcomeId><gtr:partnerContribution>Developed a protocol that will be run in Oxford that is capable of identifying and quantifying over 230 metabolites in serum.</gtr:partnerContribution><gtr:piContribution>Established a high-throughput metabolomics facility in Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fuwai Cardiovascular Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Advisor to the Fuwai Hospital Working Group for Beijing Biocentre</gtr:description><gtr:id>7F125546-51BC-40E3-B36E-A9F91533C7B9</gtr:id><gtr:impact>None.</gtr:impact><gtr:outcomeId>5447cafff0cbc8.85119771-1</gtr:outcomeId><gtr:partnerContribution>Expert Working Group organised by collaborator.</gtr:partnerContribution><gtr:piContribution>Advising on laboratories and sample repository, including ISO accreditation.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nightingale Health Ltd.</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Nightingale Health</gtr:description><gtr:id>7E35846F-4837-416A-A403-331112B007F5</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>58c141fec5b5a2.39487584-1</gtr:outcomeId><gtr:partnerContribution>Service agreement in place to allow the University of Oxford to run their NMR metabolomics protocol</gtr:partnerContribution><gtr:piContribution>Helped stablish a high-throughput NMR metabolomics facility within the University of Oxford</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford Science Fare</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>97D5334B-F043-4A7C-9A4D-F467BA7C3388</gtr:id><gtr:impact>Participation in an epidemiology game at Oxford Science Fare, June 2016</gtr:impact><gtr:outcomeId>58c122d9f0dcf0.41211674</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience hosted and organised by the NDPH Wolfson Laboratory for students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5ECB1222-A34A-43F2-87CE-D980E9DAE728</gtr:id><gtr:impact>Work experience hosted and organised by the NDPH Wolfson Laboratory for students. We provide an insight into laboratory work supporting large scale studies and ISO accreditation as a testing laboratory. For many students the work experience fulfils school study requirements for some it also helps inform career choice. Five-ten work experience students visit the NDPH Wolfson Laboratory each year. These are based locally and UK wide.</gtr:impact><gtr:outcomeId>56dee117bad4f0.49414990</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop hosted and organised by the NDPH Wolfson Laboratory for BTEC students at Mary Hare School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>73B9E42B-196B-4A70-B875-7E3AC292F192</gtr:id><gtr:impact>Workshop hosted and organised by the NDPH Wolfson Laboratory for BTEC students at Mary Hare School. We provide an insight into laboratory work supporting large scale studies and ISO accreditation as a testing laboratory. The workshop fulfils a &amp;quot;Science in industry&amp;quot; visit required for their course. The Mary Hare School is a residential co-educational community special school for deaf pupils in Newbury, Berkshire, England. Workshops have been organised in the last two years; 20th June 2013, 4th September 2014 and 14 April 2016.

None</gtr:impact><gtr:outcomeId>5447c96b3433b8.48196029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>26000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Excellence Award</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>0F2C2FA3-CD06-4376-B61F-DAF1B0F18E19</gtr:id><gtr:outcomeId>5433aa34320d18.15684928</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital funding bid</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BD3E35F9-4606-4339-A29E-1FFF17FAAFDE</gtr:id><gtr:outcomeId>58c126b08fbf69.48124693</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital Funding</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F057D9A4-042C-497D-97A1-A4D22CDF05C8</gtr:id><gtr:outcomeId>58c124bd4836e4.35854655</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>Research grant (High throughput phenotyping)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>E17AEA8E-0778-4D4F-8530-BBDB44FA4121</gtr:id><gtr:outcomeId>5433a93b0afde0.16665080</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>261000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (High throughput phenotyping)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>0676B208-D5F4-4B0B-9E10-FB379EC9DD7B</gtr:id><gtr:outcomeId>5433a9a46d6ab2.63436445</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Excellence Award</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>F41DBC5B-AD34-43E6-A230-963B31C0E389</gtr:id><gtr:outcomeId>5433aa96489d17.31675179</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital funding bid</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>62BB9E00-12B7-4AC2-A3B4-9187E083EB08</gtr:id><gtr:outcomeId>58c1266694b700.66487897</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Excellence Award</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>722EEB8B-B206-4FDA-B580-622465596D8E</gtr:id><gtr:outcomeId>5433a9e4d3f110.50573612</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Strategic Investment Award</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>2BDED9C3-9577-4084-9447-3663DD51655F</gtr:id><gtr:outcomeId>58c1255d78ccf3.05952442</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>103000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital Funding Bid</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1DC59E14-769F-4D24-9751-EB5EE4B367B7</gtr:id><gtr:outcomeId>58c123ec0d90f8.43073080</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1587500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust for CKB</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>4E3F8961-21E1-4C18-AB67-713784799A99</gtr:id><gtr:outcomeId>58c68bce4bf0e0.87338151</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:fundingOrg>Welsh Thoracic Society</gtr:fundingOrg><gtr:id>E799043F-36F4-4748-BD84-8F64F8243270</gtr:id><gtr:outcomeId>58c1402d0041c9.91952018</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (NMR)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>LipoScience, Inc.</gtr:fundingOrg><gtr:id>9A8C4B54-8FD8-45B8-9E78-E67AEAD630C1</gtr:id><gtr:outcomeId>5433aafa729a45.71994550</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:fundingOrg>Mason Medical Research Foundation</gtr:fundingOrg><gtr:id>24E6F1E7-6BB6-4166-83F6-4BB35099F265</gtr:id><gtr:outcomeId>58c140ace7a490.00834240</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:fundingOrg>The Ritchie Trust</gtr:fundingOrg><gtr:id>02A93F0C-CB8D-49D3-A6A2-E12AB24CFB91</gtr:id><gtr:outcomeId>58c1410a9de1b0.14476968</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>113000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital Funding bid</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D4155D81-C4F2-4943-A6E8-584E68B8069D</gtr:id><gtr:outcomeId>58c1260d3f2e22.60819338</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210988</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research training fellowship</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>AFBAF019-5136-462A-AC2C-C7DA37072D3C</gtr:id><gtr:outcomeId>58c126eea9c513.38906898</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CKB</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>246B9EF3-3076-47D3-8EDB-B7EB068B3354</gtr:id><gtr:outcomeId>58c68c7c0f81b0.09859151</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>203000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical research training fellowship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5AFDB5C4-6B1C-4819-B71F-52DE6D5F2ECD</gtr:id><gtr:outcomeId>58c13fd5489105.06021689</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OU Capital Fund</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>ABBE41B2-9774-4BF7-89BE-C0B74DB85757</gtr:id><gtr:outcomeId>58c125b02f7856.80048268</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>320000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (Liquid nitrogen storage facility)</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>84B82076-F0B1-4162-A099-4E02459635D9</gtr:id><gtr:outcomeId>5433a8dd77ec29.19617619</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>34683843-B650-45F1-B9C6-495D7BD3C437</gtr:id><gtr:title>Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>58c14533817a78.76040026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F1C0794-F3D8-4BF0-994A-2FA3474BA6DB</gtr:id><gtr:title>Lipids, Lipoproteins, and Metabolites and&amp;nbsp;Risk of Myocardial Infarction and&amp;nbsp;Stroke.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856bb22275735c6a7534e465be5a3e8c"><gtr:id>856bb22275735c6a7534e465be5a3e8c</gtr:id><gtr:otherNames>Holmes MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5a9821be99e561.22766337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0D17349-E46F-49E1-BA22-486867AE6156</gtr:id><gtr:title>Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults.</gtr:title><gtr:parentPublicationTitle>JAMA cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ec5d8d64b82eca349c6356a4f70572"><gtr:id>c9ec5d8d64b82eca349c6356a4f70572</gtr:id><gtr:otherNames>Millwood IY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a9820c19ac669.65474151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4235FA3-E2B4-45D1-867E-1130B9B9E805</gtr:id><gtr:title>Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ec5d8d64b82eca349c6356a4f70572"><gtr:id>c9ec5d8d64b82eca349c6356a4f70572</gtr:id><gtr:otherNames>Millwood IY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>56dec75aa06053.41532971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7A3B233-281B-454C-83DE-B4214A12E8DF</gtr:id><gtr:title>The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56dec94a2d7410.01154351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1407D8B1-1B81-4F82-82E2-8C014B241F3C</gtr:id><gtr:title>Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.</gtr:title><gtr:parentPublicationTitle>Clinica chimica acta; international journal of clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-8981</gtr:issn><gtr:outcomeId>56dec949778c07.73719945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7171E5E2-1FE6-4CAF-A20D-82F9CF9CAF9D</gtr:id><gtr:title>Diabetes and Cause-Specific Mortality in Mexico City.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d019f4aab7f190fecc70c61e63259b0"><gtr:id>0d019f4aab7f190fecc70c61e63259b0</gtr:id><gtr:otherNames>Alegre-D?az J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58c145bbc67489.61448940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAE0677D-FA70-4DC1-833C-446DC3A8D24E</gtr:id><gtr:title>Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81848088b320358bb7030f5adb9548f8"><gtr:id>81848088b320358bb7030f5adb9548f8</gtr:id><gtr:otherNames>UK HARP-III Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5a9820c217e2a7.56140077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA08C88F-B902-4874-82C7-2B2BA0216313</gtr:id><gtr:title>Role of a functional polymorphism in the F2R gene promoter in sarcoidosis.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7132476b7b5fb7940bb5148803b02ef"><gtr:id>c7132476b7b5fb7940bb5148803b02ef</gtr:id><gtr:otherNames>Plat? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>56dec949bd13c6.86781601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDFEEF69-8514-48AA-964D-B8051713694E</gtr:id><gtr:title>Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study</gtr:title><gtr:parentPublicationTitle>The Lancet Respiratory Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ed6c7c47e871a6d77496b1ecb2df855"><gtr:id>2ed6c7c47e871a6d77496b1ecb2df855</gtr:id><gtr:otherNames>Allen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9820c1e90df1.85515757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86EEE4D1-0295-4692-A588-5AD9B353E6BD</gtr:id><gtr:title>P1-412 Stability of biomarkers in plasma frozen at various temperatures for several years: implications for prospective epidemiological studies</gtr:title><gtr:parentPublicationTitle>Journal of Epidemiology &amp; Community Health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e35346ca0059a858cb4a8e9b2d9c82b"><gtr:id>7e35346ca0059a858cb4a8e9b2d9c82b</gtr:id><gtr:otherNames>Clark S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541c09fb13cc70.49324158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>143E53BA-3A2C-4731-AF7A-4EDD9CB10631</gtr:id><gtr:title>A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ec5d8d64b82eca349c6356a4f70572"><gtr:id>c9ec5d8d64b82eca349c6356a4f70572</gtr:id><gtr:otherNames>Millwood IY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58c1453328a556.98466418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99FC64E4-2487-4548-A98D-C258ED7BDD5E</gtr:id><gtr:title>Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial.</gtr:title><gtr:parentPublicationTitle>Maturitas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3c262c9ed0c7ba14ef8ac1308be4a0"><gtr:id>cd3c262c9ed0c7ba14ef8ac1308be4a0</gtr:id><gtr:otherNames>Clarke R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-5122</gtr:issn><gtr:outcomeId>56dec9499e3f88.20917919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3C1C56-9EC1-4B87-B3FB-B81B950CD9F9</gtr:id><gtr:title>Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8364111fa2552ba0254a8837987f5e2"><gtr:id>f8364111fa2552ba0254a8837987f5e2</gtr:id><gtr:otherNames>Parish S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>56dec94a71f403.25950253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>442DA65A-4D72-4815-B753-1F586968476A</gtr:id><gtr:title>Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1&amp;nbsp;Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a5589c8a4e824c68666046341ed3a4e"><gtr:id>6a5589c8a4e824c68666046341ed3a4e</gtr:id><gtr:otherNames>Tomson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>5a9820c1c33410.87790247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C78CE694-604F-4367-B1CF-EA7A96F2ACA0</gtr:id><gtr:title>Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.</gtr:title><gtr:parentPublicationTitle>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffd871a732200a1c7d46c59e7a29035f"><gtr:id>ffd871a732200a1c7d46c59e7a29035f</gtr:id><gtr:otherNames>Hin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0937-941X</gtr:issn><gtr:outcomeId>58c145bc09e639.07559576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E70846D3-AE06-4A16-8F7D-000BF64415C7</gtr:id><gtr:title>HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936b68efa866101ffd6e3c7ca8d1a1a8"><gtr:id>936b68efa866101ffd6e3c7ca8d1a1a8</gtr:id><gtr:otherNames>HPS2-THRIVE Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56dec94a080799.31457687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6BF2D23-5FC8-48F5-A71A-8E5E016EE174</gtr:id><gtr:title>Perioperative Rosuvastatin in Cardiac Surgery.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb73702747eadb6adbedb18c8a3045c"><gtr:id>aeb73702747eadb6adbedb18c8a3045c</gtr:id><gtr:otherNames>Zheng Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58c14532e9dec5.69127919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD37E9D6-16C4-4FDD-8E98-75773A90EB4A</gtr:id><gtr:title>Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a5589c8a4e824c68666046341ed3a4e"><gtr:id>6a5589c8a4e824c68666046341ed3a4e</gtr:id><gtr:otherNames>Tomson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56dec94a506440.74656743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DB96750-2A5D-4762-BD96-8F2735E4F197</gtr:id><gtr:title>Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7132476b7b5fb7940bb5148803b02ef"><gtr:id>c7132476b7b5fb7940bb5148803b02ef</gtr:id><gtr:otherNames>Plat? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn><gtr:outcomeId>56dec949df7808.13887183</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137686855</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>